Search

Cookies

We use cookies to improve your experience. By continuing, you accept our use of cookies.

Business

US Urges India to Reduce China's Dominance in Generic Drug Supply Chains

· · 3 min read

A significant portion of US generic drugs, including those from India, depend on Chinese key starting materials. The US-China Economic and Security Review Commission (USCC) urges a US-India initiative to lessen Beijing's leverage over essential medicines.

Washington is actively encouraging India to diminish China's substantial influence over the global supply of generic drug starting materials. A recent report by the US-China Economic and Security Review Commission (USCC) highlights critical vulnerabilities in the pharmaceutical supply chain, recommending a joint US-India initiative to secure essential medicines.

The USCC's 2026 Annual Report to Congress details that nearly a quarter of all active pharmaceutical ingredients (APIs) used in US generic drugs are sourced directly from China. Furthermore, a considerable 24% to 46.8% of generic daily doses distributed in the United States, even those using Indian APIs, rely on upstream Chinese key starting materials (KSMs).

China's Strategic Leverage in Pharma Production

Despite India's rise as a global manufacturing hub, particularly in pharmaceuticals, its factories remain heavily dependent on Chinese machinery, components, and raw inputs. The USCC noted that while New Delhi has taken steps to restrict Chinese involvement in sensitive sectors and subsidize domestic production, India's industrial growth has paradoxically increased its demand for Chinese equipment and technical expertise.

This dependence creates a strategic leverage point for Beijing, which has previously utilized its upstream dominance to hinder competing Indian capacity. The report cites instances where Chinese authorities recalled engineers, withheld equipment for India's electronics manufacturing, imposed export controls on battery technology, and flooded global markets with below-cost APIs and KSMs to undercut emerging Indian pharmaceutical plants.

Protecting Critical Medicine Supply Lines

A US Pharmacopeia study referenced in the report revealed that 12% of nearly 2,000 sampled APIs rely solely on China for their KSMs. These include vital hospital antibiotics, the blood thinner heparin, and the immunosuppressant mycophenolate, underscoring the severity of the supply chain risk.

In 2025, China also briefly required Indian firms to certify that certain Chinese-supplied inputs would not be re-exported to the United States. Although this requirement was suspended under a broader US-China trade détente, the Commission warned that it remains a potential tool to weaponize India's industrial reliance against American supply chains.

Proposed US-India Pharmaceutical Initiative

To counter Beijing's significant leverage over essential medicines, the USCC has included a US-India pharmaceutical initiative among its top 10 recommendations to Congress. This proposed program, named the Comprehensive Critical Drug Diversification (C2D2), aims to strengthen global pharmaceutical supply chains.

Key Components of the C2D2 Program:

  • Supply-Chain Early Warning Mechanism: To identify potential disruptions and vulnerabilities proactively.
  • Multi-Year US Government Purchasing Commitments: For medicines produced with qualifying American or trusted-partner inputs.
  • Investment in Indian Manufacturing: Support for public and private investment in Indian API and KSM production.

These investments would be contingent upon Indian API producers demonstrating minimal and declining reliance on Chinese KSMs, alongside coordinated efforts with Washington to resist predatory Chinese pricing practices. The initiative seeks to build a more resilient and diversified global pharmaceutical supply network, reducing dependence on any single nation for critical drug components.

Related